Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
Journal of Interventional Cardiology|September 25, 2012
Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA StudyJames B Hermiller, David R Rutledge, Luis Gruberg, et al.
Circulation. Cardiovascular Interventions|March 23, 2012
Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and Paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitionsM Hassan Pervaiz, Poornima Sood, Krishnankutty Sudhir, et al.
The American Journal of Cardiology|July 9, 2010
SPIRIT III JAPAN versus SPIRIT III USA: a comparative intravascular ultrasound analysis of the everolimus-eluting stentTakao Shimohama, Junya Ako, Masao Yamasaki, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|June 17, 2009
Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trialAlexandra J Lansky, Vivian G Ng, Halil Mutlu, et al.
JACC. Cardiovascular Interventions|January 15, 2011
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trialsAdriano Caixeta, Alexandra J Lansky, Patrick W Serruys, et al.
American Heart Journal|October 31, 2006
Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary deathHeidi T May, Benjamin D Horne, Jeffrey L Anderson, et al.
Circulation|January 28, 2009
Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trialGregg W Stone, Mark Midei, William Newman, et al.
The American Journal of Cardiology|March 19, 2013
Evaluation of XIENCE V everolimus-eluting and Taxus Express2 paclitaxel-eluting coronary stents in patients with jailed side branches from the SPIRIT IV trial at 2 yearsJohn K Forrest, Alexandra J Lansky, Stephanie M Meller, et al.
JACC. Cardiovascular Interventions|December 24, 2011
A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study)Mitchell W Krucoff, David R Rutledge, Luis Gruberg, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|October 5, 2010
Comparison of vascular response to zotarolimus-eluting stent vs paclitaxel-eluting stent implantation: pooled IVUS results from the ZoMaxx I and II trialsKatsuhisa Waseda, Takao Hasegawa, Junya Ako, et al.
Pageof 10